Balsalazide Disodium ( DrugBank: Balsalazide )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	4

97. Ulcerative colitis

---

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00486031 (ClinicalTrials.gov)	October 2006	11/6/2007	Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study	A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis	Inflammatory Bowel Disease;Ulcerative Colitis	Drug: Balsalazide Disodium	Bausch Health Americas, Inc.	NULL	Completed	18 Years	N/A	All	443	Phase 3	United States
2	NCT00408174 (ClinicalTrials.gov)	May 2006	4/12/2006	Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis	A Multicenter, Randomized, Double-Blind, Actively-Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3 g Bid Versus Mesalamine (5-ASA) as Asacol® 0.8 g Tid in Mildly to Moderately Active Ulcerative Colitis	Inflammatory Bowel Disease;Ulcerative Colitis	Drug: Balsalazide disodium	Bausch Health Americas, Inc.	NULL	Completed	18 Years	N/A	All	400	Phase 3	United States
3	NCT00269438 (ClinicalTrials.gov)	December 2005	22/12/2005	New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis	Phase 3 Study to Establish the Efficacy and Safety of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium Dosed Twice Daily in Achieving Clinical Improvement in Subjects With Mildly to Moderately Active Ulcerative Colitis After 8 Weeks of Therapy	Ulcerative Colitis	Drug: 5 ASA, enemas, suppositories, corticosteroids	Bausch Health Americas, Inc.	NULL	Completed	18 Years	80 Years	All	225	Phase 3	United States
4	NCT00618202 (ClinicalTrials.gov)	May 2005	30/1/2008	A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions	A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions	Ulcerative Colitis	Drug: Balsalazide	Roxane Laboratories	NULL	Completed	18 Years	45 Years	All	52	N/A	United States